Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Massachusetts General Hospital
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Novartis
M.D. Anderson Cancer Center
Incyte Corporation
National Cancer Institute (NCI)
iOnctura
Massachusetts General Hospital
National Cancer Institute (NCI)
Novartis
Dana-Farber Cancer Institute
Massachusetts General Hospital
National Cancer Institute (NCI)
CareDx
Center for International Blood and Marrow Transplant Research
National Institutes of Health Clinical Center (CC)
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
Cogent Biosciences, Inc.
Orca Biosystems, Inc.
Auron Therapeutics, Inc.
Emory University
Washington University School of Medicine
M.D. Anderson Cancer Center
Faron Pharmaceuticals Ltd
City of Hope Medical Center
Dartmouth-Hitchcock Medical Center